Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the tolerability and toxicity of different dose of
anlotinib combination with concurrent chemoradiotherapy in the treatment of limited-stage
SCLC patients.
Phase:
Phase 1
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital